1-4 of 4
Xia Tong, M.Sc
Close
Sort by
Journal Articles

Efficacy of an Antagonistic Anti-CD40 Monoclonal Antibody, HCD122 (CHIR-12.12), in Preclinical Models of Human Non-Hodgkin’s Lymphoma and Hodgkin’s Disease.

Li Long, PhD, Montesa Patawaran, B.Sc., Xia Tong, M.Sc., Seema Kantak, Ph.D., Sharon L. Aukerman, Ph.D., Nancy Pryer, Ph.D., Mohammad Luqman, Ph.D.
Journal: Blood
Blood (2006) 108 (11): 230.
https://doi.org/10.1182/blood.V108.11.230.230
Published: 2006
Journal Articles

Antagonist Anti-CD40 Antibody, CHIR-12.12, Induces ADCC, Inhibits Tumor Growth, and Prolongs Survival in a Human Multiple Myeloma Xenograft Model.

Li Long, PhD, Xia Tong, M.Sc, Montesa Patawaran, B.Sc, Sharon L. Aukerman, PhD, Bahija Jallal, PhD, Mohammad Luqman, PhD
Journal: Blood
Blood (2005) 106 (11): 3470.
https://doi.org/10.1182/blood.V106.11.3470.3470
Published: 2005
Journal Articles

Antagonist Anti-CD40 Antibody CHIR-12.12 Causes Tumor Regression and Prolongs Survival in Multiple Myeloma Xenograft Models.

Li Long, Ph.D., Xia Tong, M.Sc., Montesa Patawaran, B.Sc., Lea Aukerman, Ph.D., Bahija Jallal, Ph.D., Mohammad Luqman, Ph.D.
Journal: Blood
Blood (2004) 104 (11): 4888.
https://doi.org/10.1182/blood.V104.11.4888.4888
Published: 2004
Journal Articles

Antagonist Anti-CD40 Monoclonal Antibody, CHIR-12.12, Inhibits Growth of a Rituximab-Resistant NHL Xenograft Model and Achieves Synergistic Activity When Combined with Ineffective Rituximab.

Li Long, Ph.D., Xia Tong, M.Sc., Montesa Patawaran, B.Sc., Lea Aukerman, Ph.D., Julie Klinger, Ph.D., Bahija Jallal, Ph.D., Mohammad Luqman, Ph.D.
Journal: Blood
Blood (2004) 104 (11): 3281.
https://doi.org/10.1182/blood.V104.11.3281.3281
Published: 2004